Data di Pubblicazione:
2023
Abstract:
Trastuzumab deruxtecan is an HER 2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs patient-derived xenografts (PDX) models from human brain metastases and phase 0 and window of opportunity trials are of utmost importance.
Tipologia CRIS:
03A-Articolo su Rivista
Elenco autori:
Soffietti, Riccardo; Pellerino, Alessia
Link alla scheda completa:
Pubblicato in: